好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Slow Blood-Brain Barrier Leakage Is Associated with Acute Brain Ischemia and Portends Increased Risk for Delayed Stroke
Cerebrovascular Disease and Interventional Neurology
S47 - Stroke Outcomes and Recurrence (2:06 PM-2:17 PM)
007
The diagnosis of transient ischemic attack (TIA) is challenging. Evidence of acute ischemia on diffusion-weighted imaging (DWI) is highly variable and confirmed in only about one-third of patients. BBBD is a prominent feature in cerebral ischemia and a key mechanism underlying delayed neurological complications. Yet, to date, no clinical studies have characterized BBBD in TIA.

To assess blood-brain barrier dysfunction (BBBD) mapping in patients with transient neurological deficit, as a diagnostic and predictive biomarker required for risk stratification and stroke prevention.

Observational, single-center prospective cohort study conducted in a tertiary stroke referral center from October 2012 through December 2016. We used dynamic contrast-enhanced MRI for quantification of fast and slow BBBD in 57 patients with TIA/minor stroke and 50 healthy controls. Patients were followed until October 31, 2017.
Mean age of patients (64.9% men) was 58.4 years. Thirty-one (54.4%) had negative and 26 (45.6%) had positive DWI. The extent of BBBD was significantly higher in patients compared to controls (65.3% men; mean age, 40.7 years; fast BBBD, P<.001; slow BBBD, P=.002) and to age-matched controls (n=23, 55.8 years; fast, P<.001, slow, P=.05). Slow but not fast BBBD was significantly more prevalent in patients with positive DWI (P=.05). Slow BBBD corresponded with the clinical presentation in 41 patients (72%). Patients who later developed new stroke (n=7) did not differ by their initial DWI but had higher degree of slow BBBD (P=.03). Patients with extensive BBBD (≥ interquartile range above the median of pathological voxels) had a risk ratio of 5.35 (95% CI=1.50-19.09) for delayed stroke, compared to 0.89 (95% CI=0.22-3.63) for patients with positive DWI.
We propose a quantitative approach for detection of microvascular pathology and subtle brain ischemia. Slow BBBD is a potential biomarker for the development of delayed stroke.
Authors/Disclosures
Yonatan Serlin, MD (McGill University)
PRESENTER
Dr. Serlin has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Gal Ifergane, MD (Soroka University Medical Center) Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medison pharma. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceretrieve. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medison pharma. Dr. Ifergane has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Ifergane has received research support from Teva.
No disclosure on file
Jeffrey Minuk, MD (Jewish General Hospital SMBD) No disclosure on file
No disclosure on file
No disclosure on file